Cited by 32Schizophrenia research and treatmentPharmacovigilance and Adverse Drug ReactionsPharmaceutical Practices and Patient Outcomes

Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia

Roy-Desruisseaux, Jessika, Landry, Julie, Bocti, Christian, Tessier, Daniel, Hottin, Paule, Trudel, Jean-François·2011·Annals of Pharmacotherapy

Abstract

OBJECTIVE: To report a case of probable domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman. CASE SUMMARY: A 75-year-old woman was first assessed for cognitive decline and personality changes. On clinical examination, diffuse choreoathetoid movements were noted. Chronic domperidone use seemed the most likely cause for the movement disorder and was abruptly discontinued. Within a few days, she developed a severe psychotic syndrome with Capgras delusions; the movement disorder continued unabated. Both the movement disorder and psychotic symptoms promptly remitted with risperidone treatment. DISCUSSION: Domperidone has, on rare occasions, been associated with acute extrapyramidal syndromes, especially in young children, but, to our knowledge, this is the first case of domperidone-induced tardive dyskinesia and withdrawal psychosis, adverse effects associated with chronic central nervous system dopaminergic blockade. Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier. However, blood-brain barrier alterations occur with aging and dementia, which may explain central nervous system penetration of domperidone in our patient, diagnosed with probable frontotemporal dementia. The association was rated as probable on the Naranjo probability scale. CONCLUSIONS: Chronic use of domperidone may, on rare occasions, induce neuropsychiatric syndromes similar to those seen with the use of antipsychotics. This may be more likely in situations in which the blood-brain barrier is damaged, as in vascular and degenerative dementias.

Integrity signals

Registry

Crossref · 10.1345/aph.1q214

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People with no history of psychosis who develop psychotic symptoms on abrupt cessation of dopamine antagonists used in a non-psychiatric context provide support for the hypothesis that dopaminergic hypersensitivity contributes to early relapse into psychosis after antipsychotic cessation.

    “People with no history of psychosis who develop psychotic symptoms on abrupt cessation of dopamine antagonists used in a non-psychiatric context (eg, breast milk stimulation or treatment of nausea) provide support for this hypothesis (table 1).”
  • Eight case reports describe psychotic symptoms arising in 13 patients with no history of psychosis after the abrupt withdrawal of dopamine antagonists.

    “Eight case reports describe psychotic symptoms arising in 13 patients with no history of psychosis after the abrupt withdrawal of dopamine antagonists (table 1).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Roy-Desruisseaux, J., Landry, J., Bocti, C., Tessier, D., Hottin, P., & Trudel, J.-F.
Affiliations
Université de Sherbrooke (CA)
Venue
Annals of Pharmacotherapy
Published
2011-08-18
Volume
45
Issue
9
Pages
1166-1166
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2130369866
Cited by
32
References
28
Citations by year
2026: 3 · 2025: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 2 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 1
FWCI
1.75
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
domperidone, tardive dyskinesia, drug-induced psychosis, dementia, frontotemporal dementia, blood-brain barrier, dopamine D2 receptor antagonists, extrapyramidal symptoms, risperidone, Capgras delusion, adverse drug reactions, older women
MeSH terms
Aged, Blood-Brain Barrier, Dementia, Domperidone, Dyskinesia, Drug-Induced, Female, Humans, Psychotic Disorders, Substance Withdrawal Syndrome, Dopamine Antagonists, Risperidone, Dopamine D2 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review